|
시장보고서
상품코드
2102012
만성 염증성 탈수초성 다발성 신경병증(CIDP) 시장 규모, 점유율 및 성장 분석 : 치료법별, 투여 경로별, 유통 채널별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)Chronic Inflammatory Demyelinating Polyneuropathy Cidp Market Size, Share, and Growth Analysis, By Treatment Type, By Route of Administration, By Distribution Channel, By End User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 만성 염증성 탈수초성 다발성 신경병증(CIDP) 시장 규모는 2024년에 17억 2,000만 달러로 평가되며, 2025년 18억 5,000만 달러에서 2033년까지 32억 8,000만 달러로 확대하며, 예측 기간에 CAGR은 7.4%입니다(2026-2033년).
세계의 만성 염증성 탈수초성 다발성 신경염(CIDP) 시장은 운동 기능 및 감각 기능에 심각한 영향을 미치는 희귀 자가면역성 신경 장애에 대한 진단제, 생물제제 및 지지요법을 포괄합니다. 이 질환은 환자의 삶의 질을 현저히 저하시킬 뿐만 아니라, 장기간에 걸친 정맥내 면역글로불린(IVIG) 치료에 따른 고비용도 수반하므로 비용 대비 효과가 높은 대체요법에 대한 수요가 증가하고 있습니다. 피하 투여형 면역글로불린(SCIG) 및 Fc 변형 모노클로널 항체의 도입으로, 주사 횟수 감소를 통해 환자의 복약 순응도가 향상되어 시장 성장을 촉진하고 있습니다. SCIG는 의료비 절감 및 재입원율 감소로 이어진다는 증거가 있으며, 보험사의 급여 범위 확대가 촉진되고 있습니다. 생명공학 기업이 혁신적인 치료법 개발에 투자함에 따라 특히 미충족 의료 수요가 큰 개발도상국 시장에서 새로운 기회가 창출되고 있습니다.
전 세계 만성 염증성 탈수초성 다발성 신경염(CIDP) 시장의 성장 요인
의료 전문가들 사이에서 만성 염증성 탈수초성 다발성 신경염(CIDP)에 대한 인식이 높아지고 있는 것이 진단 및 의뢰 과정의 개선에 크게 기여하고 있으며, 그 결과 새로운 치료법의 잠재적 환자층이 확대되고 있습니다. 임상의들이 특징적인 증상을 보다 정확하게 파악할 수 있게 됨에 따라 질병 수정 치료를 고려하는 경향이 강해지고 있으며, 그 결과 처방률이 상승하고 혁신적인 치료법에 대한 수용이 확산되고 있습니다. 이러한 인식의 증대는 학제 간 협력을 촉진하고 치료 과정을 효율화할 뿐만 아니라, 첨단 치료 옵션에 대한 수요를 높이고 있습니다. 신속한 개입은 환자에게 이익을 가져다줄 뿐만 아니라, 신제품의 임상적 유효성을 입증하는 결과로 이어져, 이를 통해 연구개발에 대한 추가 투자가 촉진됩니다.
전 세계 만성 염증성 탈수초성 다발성 신경염(CIDP) 시장의 제약 요인
만성 염증성 탈수초성 다발성 신경염(CIDP)에 대해 전 세계에서 인정된 바이오마커가 존재하지 않는다는 점은 조기 및 정확한 진단을 내리는 데 있으며, 큰 과제가 되고 있으며, 이는 진단 지연이나 오분류로 이어질 가능성이 있습니다. 신뢰할 수 있는 검사 지표가 부족하므로 의료진은 종종 배제 진단법이나 주관적인 임상 평가에 의존할 수밖에 없으며, 그 결과 적절한 치료 시작이 지연될 가능성이 있습니다. 이러한 진단상의 불확실성으로 인해 보다 명확한 진단이 확정될 때까지 임상의들은 혁신적이면서도 비용이 높을 수 있는 치료법의 처방에 신중을 기할 가능성이 있습니다. 그 결과, 이러한 요인들이 시장 확대를 현저히 제한하고 있으며, CIDP 분야에서의 새로운 치료법 도입을 적시에 이루어지지 못하게 하고 있습니다.
전 세계 만성 염증성 탈수초성 다발성 신경염(CIDP) 시장 동향
전 세계 만성 염증성 탈수초성 다발성 신경염(CIDP) 시장은 혁신적인 생물제제의 발전에 힘입어 현저한 변화를 겪고 있습니다. 생명공학 기업은 특히 항체 및 재조합 단백질 개발을 통해 면역 기전을 표적으로 하는 차세대 치료법에 주력하고 있습니다. 선택성 향상, 투여 빈도 감소, 그리고 환자의 복약 순응도 강화에 중점을 두고 있다는 점은 치료 선택지에 있으며, 혁신적인 접근 방식을 보여줍니다. 전문 제약 기업과 학술연구 기관 간의 협력을 통해 중개 연구(translational research) 활동이 강화되는 한편, 규제 당국도 새로운 임상 평가 지표에 대해 점점 더 긍정적인 태도를 보이고 있습니다. 이러한 변화하는 상황에 따라 바이오의약품은 기존 치료법을 대체할 유력한 선택지로 자리매김하고 있으며, 전 세계적인 장기 관리 전략의 재정의로 이어질 가능성이 있습니다.
자주 묻는 질문
목차
서론
조사 방법
개요
시장 역학과 전망
주요 시장 인사이트
세계의 만성 염증성 탈수초성 다발성 신경병증(CIDP) 시장 규모 : 치료 유형별
세계의 만성 염증성 탈수초성 다발성 신경병증(CIDP) 시장 규모 : 투여 경로별
세계의 만성 염증성 탈수초성 다발성 신경병증(CIDP) 시장 규모 : 유통 채널별
세계의 만성 염증성 탈수초성 다발성 신경병증(CIDP) 시장 규모 : 최종사용자별
세계의 만성 염증성 탈수초성 다발성 신경병증(CIDP) 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSAGlobal Chronic Inflammatory Demyelinating Polyneuropathy CIDP Market size was valued at USD 1.72 Billion in 2024 and is poised to grow from USD 1.85 Billion in 2025 to USD 3.28 Billion by 2033, growing at a CAGR of 7.4% during the forecast period (2026-2033).
The global market for chronic inflammatory demyelinating polyneuropathy (CIDP) encompasses diagnostics, biologics, and supportive therapies for a rare autoimmune neuropathy that severely affects motor and sensory functions. The disease not only significantly diminishes patient quality of life but also involves the high expenses associated with long-term intravenous immunoglobulin (IVIG) treatments, spurring the need for cost-effective alternatives. The introduction of subcutaneous immunoglobulin (SCIG) and Fc-engineered monoclonal antibodies is driving market growth by promoting patient adherence through fewer required infusions. Evidence shows that SCIG leads to reduced healthcare costs and lower hospital readmission rates, encouraging insurers to enhance reimbursement. As biotech firms invest in the development of innovative therapies, new opportunities are emerging, particularly in developing markets with considerable unmet needs.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Chronic Inflammatory Demyelinating Polyneuropathy CIDP market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Chronic Inflammatory Demyelinating Polyneuropathy CIDP Market Segments Analysis
Global chronic inflammatory demyelinating polyneuropathy CIDP market is segmented by treatment type, route of administration, distribution channel, end user and region. Based on treatment type, the market is segmented into corticosteroids, intravenous immunoglobulin (IVIg), subcutaneous immunoglobulin (SCIg), plasma exchange (Plasmapheresis), immunosuppressants & immunomodulators and others. Based on route of administration, the market is segmented into intravenous, subcutaneous and oral. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, specialty pharmacies and online pharmacies. Based on end user, the market is segmented into hospitals, neurology clinics, ambulatory infusion centers and home healthcare settings. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Chronic Inflammatory Demyelinating Polyneuropathy CIDP Market
The rising awareness of chronic inflammatory demyelinating polyneuropathy (CIDP) among healthcare professionals has significantly contributed to improved detection and referral processes, thereby expanding the potential patient demographic for novel therapies. As clinicians become more attuned to characteristic symptomatology, they are increasingly inclined to explore disease-modifying treatments, resulting in elevated prescription rates and wider acceptance of innovative treatment methods. This enhanced awareness fosters interdisciplinary collaboration, streamlining care processes and increasing the demand for advanced therapeutic options. Prompt intervention not only benefits patients but also underscores the clinical efficacy of new products, thereby encouraging further investment in research and development.
Restraints in the Global Chronic Inflammatory Demyelinating Polyneuropathy CIDP Market
The absence of universally recognized biomarkers for chronic inflammatory demyelinating polyneuropathy (CIDP) poses significant challenges in achieving early and accurate diagnoses, resulting in delays and potential misclassifications. As reliable laboratory markers are scarce, healthcare professionals often rely on exclusionary methods and subjective clinical evaluations, which can postpone the initiation of suitable treatments. This diagnostic uncertainty may cause clinicians to be cautious about prescribing innovative and potentially expensive therapies until a clearer diagnosis is confirmed. Consequently, these factors considerably restrict market expansion and hinder the timely adoption of new treatment alternatives in the CIDP arena.
Market Trends of the Global Chronic Inflammatory Demyelinating Polyneuropathy CIDP Market
The Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market is experiencing a notable shift driven by the advancement of innovative biologics. Biotech companies are intensifying their focus on next-generation therapies, particularly targeting immune mechanisms through antibody and recombinant protein development. The emphasis on selectivity, reduced infusion frequency, and improved patient adherence marks a transformative approach in treatment options. Collaborations between specialty pharmaceutical firms and academic research centers enhance translational efforts, while regulatory bodies exhibit increasing receptiveness to novel clinical endpoints. This evolving landscape is positioning biologics as a compelling alternative to traditional therapies, potentially redefining long-term management strategies worldwide.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Chronic Inflammatory Demyelinating Polyneuropathy Cidp Market Size by Treatment Type & CAGR (2026-2033)
- Market Overview
- Corticosteroids
- Intravenous Immunoglobulin (IVIg)
- Subcutaneous Immunoglobulin (SCIg)
- Plasma Exchange (Plasmapheresis)
- Immunosuppressants & Immunomodulators
- Others
Global Chronic Inflammatory Demyelinating Polyneuropathy Cidp Market Size by Route of Administration & CAGR (2026-2033)
- Market Overview
- Intravenous
- Subcutaneous
- Oral
Global Chronic Inflammatory Demyelinating Polyneuropathy Cidp Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Specialty Pharmacies
- Online Pharmacies
Global Chronic Inflammatory Demyelinating Polyneuropathy Cidp Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Neurology Clinics
- Ambulatory Infusion Centers
- Home Healthcare Settings
Global Chronic Inflammatory Demyelinating Polyneuropathy Cidp Market Size & CAGR (2026-2033)
- North America (Treatment Type, Route of Administration, Distribution Channel, End User)
- US
- Canada
- Europe (Treatment Type, Route of Administration, Distribution Channel, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Treatment Type, Route of Administration, Distribution Channel, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Treatment Type, Route of Administration, Distribution Channel, End User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Treatment Type, Route of Administration, Distribution Channel, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- CSL Behring LLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Grifols SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Octapharma AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Kedrion Biopharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biotest AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- LFB USA Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Argenx SE
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson Services Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Viatris Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sandoz International GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lupin Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
